Supernus Pharmaceuticals SUPN
NASDAQ SUPN
$42.18 -0.86 (-2.00%)
At close: Oct 1, 2026 · 4:00 PM EDT

Supernus Pharmaceuticals (SUPN) Cash from Financing Activities (2011 - 2026)

Updated

Supernus Pharmaceuticals (SUPN) posted Cash from Financing Activities of -$7.2 million for Q2 2026, compared with $935,000 a year earlier.

Analysis

Supernus Pharmaceuticals (SUPN) Cash from Financing Activities (2011 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, Cash from Financing Activities at Supernus Pharmaceuticals was $31.51 million; for FY2025, it was $9.13 million, down 25.1% from FY2024.

  • Annual Cash from Financing Activities shows a five-year compound annual growth rate of 20.7% (FY2020 to FY2025).
  • In prior years, Supernus Pharmaceuticals' Cash from Financing Activities was $12.19 million in FY2024, -$397.88 million in FY2023, -$10.48 million in FY2022 and -$130.42 million in FY2021.
  • The Q2 2026 figure stands as the lowest quarterly Cash from Financing Activities since Q1 2025.
  • On a year-over-year basis, Cash from Financing Activities increased in three of the last four quarters, with growth averaging 256.4%.
  • The strongest year-over-year quarter for Cash from Financing Activities in the past five years was Q3 2025, with growth of 585.1%; the weakest was Q1 2024, with a decline of 98.0%.
  • According to Business Quant data, Cash from Financing Activities for the three prior quarters was $9.12 million (Q1 2026), $8.53 million (Q4 2025) and $21.07 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -8.78 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -5.05 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 1.76 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -2.02 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -47.00 Mn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -1.48 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 2.34 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -3.66 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -426.70 Mn
10 Supernus Pharmaceuticals 2.50 Bn 1.16 Bn 185.39 Mn -7.20 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -7.20 Mn
Mar 31, 2026 9.12 Mn
Dec 31, 2025 8.53 Mn
Sep 30, 2025 21.07 Mn
Jun 30, 2025 935,000.00
Mar 31, 2025 -21.40 Mn
Dec 31, 2024 5.89 Mn
Sep 30, 2024 3.08 Mn
Jun 30, 2024 1.66 Mn
Mar 31, 2024 1.57 Mn
Dec 31, 2023 1.09 Mn
Sep 30, 2023 -230,000.00
Jun 30, 2023 -478.92 Mn
Mar 31, 2023 80.17 Mn
Dec 31, 2022 2.83 Mn
Sep 30, 2022 6.46 Mn
Jun 30, 2022 2.27 Mn
Mar 31, 2022 -22.03 Mn
Dec 31, 2021 -136.74 Mn
Sep 30, 2021 1.32 Mn
API Access

Supernus Pharmaceuticals Cash from Financing Activities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-financing-activities&ticker=SUPN&period=max&api_key=YOUR_API_KEY